Monomeric gremlin is a novel vascular endothelial growth factor receptor-2 antagonist
Metrics: PDF 862 views | HTML 805 views | ?
Elisabetta Grillo1, Cosetta Ravelli1, Michela Corsini2, Kurt Ballmer-Hofer3, Luca Zammataro4, Pasqua Oreste5, Giorgio Zoppetti5, Chiara Tobia1, Roberto Ronca1, Marco Presta1,2,*, Stefania Mitola1,*
1Experimental Oncology and Immunology, Department of Molecular and Translational Medicine, University of Brescia, Brescia, 25123, Italy
2Experimental Oncology and Immunology, Department of Molecular and Translational Medicine, National Institute of Neurosciences, University of Brescia, Brescia, 25123, Italy
3Biomolecular Research, Molecular Cell Biology, Paul Scherrer Institut, Villigen, 5232, Switzerland
4Center of Genomics Science of IIT@SEMM, Milan, 20139, Italy
5Glycores2000, Milan, 20155 Italy
Marco Presta, e-mail: email@example.com
Stefania Mitola, e-mail: firstname.lastname@example.org
Keywords: gremlin, BMP, VEGFR2 antagonist, angiogenesis, oligomerization
Received: September 22, 2015 Accepted: March 31, 2016 Published: May 11, 2016
Angiogenesis plays a key role in various physiological and pathological conditions, including inflammation and tumor growth. The bone morphogenetic protein (BMP) antagonist gremlin has been identified as a novel pro-angiogenic factor. Gremlin promotes neovascular responses via a BMP-independent activation of the vascular endothelial growth factor (VEGF) receptor-2 (VEGFR2). BMP antagonists may act as covalent or non-covalent homodimers or in a monomeric form, while VEGFRs ligands are usually dimeric. However, the oligomeric state of gremlin and its role in modulating the biological activity of the protein remain to be elucidated.
Here we show that gremlin is expressed in vitro and in vivo both as a monomer and as a covalently linked homodimer. Mutagenesis of amino acid residue Cys141 prevents gremlin dimerization leading to the formation of gremlinC141A monomers. GremlinC141A monomer retains a BMP antagonist activity similar to the wild-type dimer, but is devoid of a significant angiogenic capacity. Notably, we found that gremlinC141A mutant engages VEGFR2 in a non-productive manner, thus acting as receptor antagonist. Accordingly, both gremlinC141A and wild-type monomers inhibit angiogenesis driven by dimeric gremlin or VEGF-A165. Moreover, by acting as a VEGFR2 antagonist, gremlinC141A inhibits the angiogenic and tumorigenic potential of murine breast and prostate cancer cells in vivo.
In conclusion, our data show that gremlin exists in multiple forms endowed with specific bioactivities and provide new insights into the molecular bases of gremlin dimerization. Furthermore, we propose gremlin monomer as a new inhibitor of VEGFR2 signalling during tumor growth.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.